Natural history of perianal crohn's disease after fecal diversion

Inflammatory Bowel Diseases

Volumn 20, Issue 12, 2014, Pages 2260-2265

  Sauk, Jenny ^a   Nguyen, Deanna ^a   Yajnik, Vijay ^a   Khalili, Hamed ^a   Konijeti, Gauree ^a   Hodin, Richard ^a   Bordeianou, Liliana ^a   Shellito, Paul ^a   Sylla, Patricia ^a   Korzenik, Joshua ^b   Friedman, Sonia ^b   Ananthakrishnan, Ashwin N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Crohn's disease; Diversion; Ileostomy; Perianal disease; Surgery

Indexed keywords

CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; NATALIZUMAB; THALIDOMIDE; USTEKINUMAB;

ADOLESCENT; ADULT; ANUS FISTULA; ARTICLE; BIOLOGICAL THERAPY; CHILD; CLINICAL ARTICLE; COLITIS; CROHN DISEASE; FECAL DIVERSION; FEMALE; FOLLOW UP; HISTORY; HUMAN; INFECTION CONTROL; MALE; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; SEPSIS; SMOKING; STENOSIS; STOMA; UNSPECIFIED SIDE EFFECT; AGED; ANUS DISEASES; FECES; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANUS DISEASES; CHILD; CROHN DISEASE; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OSTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84925798898     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000216     Document Type: Article

References (18)

1. Mueller MH, Geis M, Gatzle J, et al. Risk of fecal diversion in complicated perianal Crohn's disease. J Gastrointest Surg. 2007;11:529-537.
2. Oberhelman HA, Kohatsu S, Taylor KB, et al. Diverting ileostomy in the surgical management of anal and perianal Crohn's disease of the colon. Am J Surg. 1968;115:231-240.
3. Burman JM, Thompson M, Cooke WT, et al. The effects of diversion of intestinal contents on the progress of Crohn's disease of the large bowel. Gut. 1971;2:11.
4. Frizelle FA, Santoro GA, Peberton JH. The management of perianal Crohn's disease. Int J Colorectal Dis. 1996;11:227-237.
5. D'Haens G, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
6. Galandiuk S, Kimberling J, Al-Mishlab TG, et al. Perianal Crohn's disease: predictors of need for permanent diversion. Ann Surg. 2005;241: 796-802.
7. Hong MKH, Lynch AC, Bell S, et al. Faecal diversion in the management of perianal Crohn's disease. Colorectal Dis. 2010;13:171-176.
8. Fry RD, Shemesh EI, Kodner IJ, et al. Techniques and results in the management of anal and perianal Crohn's disease. Surg Gynecol Obstet. 1989;168:42-48.
9. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340: 1398-1405.
10. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Eng J Med. 2004;350:876-885.
11. Oxford EC, Nguyen DD, Sauk J, et al. Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol. 2013;108:1123-1129.
12. Desai D, Zator ZA, deSilva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:309-315.
13. Uzzan M, Stefanescu C, Maggiori L, et al. Case series: does a combination of anti-TNF antibodies and transient ileal fecal stream diversion in severe Crohn's colitis with perianal fistula prevent definitive stoma? Am J Gastroenterol. 2013;108:1666-1668.
14. Kasparek MS, Glatzle J, Temeltcheva T, et al. Long-term quality of life with Crohn's disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum. 2007;50:2067-2074.
15. Columbel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Eng J Med. 2010;362: 1383-1395.
16. Savoye-Collet C, Savoye G, Koning E, et al. Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis. 2011; 17:1751-1758.
17. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet. 2008;371:660-667.
18. Ordas I, Feagan B, Sandborn W. Early use of immunosuppresives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011;60:1754-1763.